These results indicate that the loss of KRAS in pancreatic tumor cells is associated with the activation of TGF-beta/SMAD4 pathway, delay in tumor growth, and a less differentiated tumor phenotype. The gene discussed is KRAS; the disease is pancreatic neoplasm.